Incyte nabs priority review for bile duct cancer drug; Temasek shows interest in another Woodford darling — report
→ Incyte’s decision to stop co-funding baricitinib in favor of other pipeline opportunities is paying off, as the FDA grants priority review to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
